SavedAdd your journal

Journals / The anatolian journal of family medicine (Online) / 2021 / Cilt: 4 - Sayı: 1

A Review of Homocysteine as a Diagnostic Tool for Diabetic Retinopathy

Aleeza FATİMA
Mohammed CHANNA
Kalina TRİFONOVA
Kiril SLAVEYKOV
Pages
2–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum Hcy levels could be used to assess microvascular risksforthe development and progression of DR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this systematic review is to identify plasma homocysteine (Hcy) as a screening and diagnostic indi- cator for assessing diabetic retinopathy (DR) risk in patients with type 2 diabetes mellitus.
📊
Key Findings & Data:Following PRISMA guidelines, data was gathered from publications between 2000−2019 from the Springer, JAMA, Lancet, and PubMed databases, as well as from diabetes-specific journals.
💡
Conclusion & Impact:Serum Hcy levels could be used to assess microvascular risksforthe development and progression of DR.
🔬Design:Lab & Field Experiment
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Özet

The aim of this systematic review is to identify plasma homocysteine (Hcy) as a screening and diagnostic indi- cator for assessing diabetic retinopathy (DR) risk in patients with type 2 diabetes mellitus. Following PRISMA guidelines, data was gathered from publications between 2000−2019 from the Springer, JAMA, Lancet, and PubMed databases, as well as from diabetes-specific journals. Observational, experimental, and multi-ethnic studies, meta-analyses, systematic reviews were included and studies that did not measure plasma Hcy, or included only patients with type 1 diabetes were excluded. The collected results were pooled and analysed for this systematic review. The majority of studies suggested an affirmative relationship exists between hy- perhomocysteinemia (HHcy) and DR, whereas some studies showed only limited clinical significance. HHcy is considered a pivotal risk factor for macular edema progression in patients with DR. Serum Hcy levels could be used to assess microvascular risksforthe development and progression of DR.

🔖

Cite This Article

FATİMA, A., CHANNA, M., TRİFONOVA, K., SLAVEYKOV, K. (2021). A Review of Homocysteine as a Diagnostic Tool for Diabetic Retinopathy. The anatolian journal of family medicine (Online), Cilt: 4 - Sayı: 1, 2–6. https://ajindex.com/articles/364985

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Johns Hopkins University & Medicine. Coronavirus Re- source Center. Available at: https://coronavirus.jhu.edu/ map.html. Accessed Oct 27, 2020
  2. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol 2020;45(8):100618
  3. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E,; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implica- tions for prevention, antithrombotic therapy, and fol- low-up: JACC state-of-the-art review. J Am Coll Cardiol 2020;75(23):2950–73
  4. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020;10(6):537–40
  5. Nelson P, Rylance P, Roden D, Trela M, Tugnet N. Viruses as potential pathogenic agents in systemic lupus ery- thematosus. Lupus 2014;23(6):596–605
  6. WHO. Clinical management of COVID-19. Interim guid- ance. 27 May 2020. Available at: https://www.who.int/ publications/i/item/clinical-management-of-covid-19. Accessed May 27, 2020
  7. University of Oxford. News and events. Dexamethasone reduces death in hospitalised patients with severe res- piratory complications of COVID-19. Available at: http:// www.ox.ac.uk/news/2020-06-16-dexamethasone-reduces-death-hospitalise- d-patients-severe-respiratory-complications. Accessed June 16, 2020
  8. RECOVERY Collaborative Group, Horby P, Lim WS, Em- berson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19 - Preliminary report. N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436. [Epub ahead of print]
  9. Dall'Era M, Wofsy D. Clinical Manifestations of Systemic Lupus Erythematosus. Firestein GS, Budd RC, Gabriel SE, MacInnes IB, O’Dell JR, eds. Kelley and Firestein's Text- book of Rheumatology. 10th ed. Philadelphia, Pa: Else- vier Saunders; 2017. 1345-67
  10. Chowdhary VR. Broad Concepts in Management of Systemic Lupus Erythematosus. Mayo Clin Proc. 2017 May;92(5):744-761.